How effective is the antidepressant drug rasagiline?

Rasagiline (Rasagiline) mainly inhibits the activity of monoamine oxidase B (MAO-B) and prevents the breakdown of the neurotransmitter dopamine, thereby increasing the level of dopamine in the synaptic cleft. This mechanism of action makes rasagiline highly effective in antidepressant and treatment of Parkinson's disease. Compared with first-generation monoamine oxidase inhibitors, rasagiline's inhibitory effect is 5-10 times stronger, and its metabolite is an inactive non-amphetamine substance, so its side effects are relatively minor.

Although rasagiline was originally developed as an antidepressant, it is more commonly used in clinical practice to treat Parkinson's disease. However, judging from its mechanism of action, rasagiline also theoretically has certain antidepressant effects. By increasing dopamine levels in the brain, rasagiline may help improve symptoms of depression. However, there is currently a lack of large-scale clinical research data to support the specific efficacy of rasagiline in antidepressant.

Rasagiline is widely recognized for its efficacy in treating Parkinson's disease. Multiple double-blind randomized controlled trials have shown that rasagiline can significantly improve symptoms of Parkinson's disease patients, such as stiffness and slowness of movement. In addition, rasagiline can also improve the efficacy of dopa preparations in patients who have experienced decline in long-term use. More importantly, there is more evidence that rasagiline has certain neuroprotective effects, which may help delay the progression of Parkinson's disease.

Rasagiline is relatively safe and has few side effects. Common side effects include headache, dizziness, etc., but they are usually mild and tolerable. The incidence of serious side effects is low, but you still need to be alert to potential risks such as allergic reactions and serotonin syndrome.